Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 08, 2023 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Expands Epilepsy Development Expertise with New Appointments

Recognized epileptologist and medical affairs leader, Manoj Malhotra, M.D., joins as Chief Medical Officer Drug discovery and development scientist and soticlestat co-inventor, Toshiya Nishi, D.V.M.,...
January 05, 2023 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Dosed Healthy Volunteers with OV329 in Phase 1 Trial

NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives...
December 02, 2022 10:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics to Present Data on Its Epilepsy Programs at American Epilepsy Society Annual Meeting (2022)

Preclinical data demonstrate potential efficacy and safety of OV329 at low, chronic dosing, suggesting an improved profile compared to other GABA-aminotransferase inhibitors Data from the NIH/NINDs...
November 08, 2022 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights

Ovid intends to initiate a Phase 1 study in healthy volunteers in Q4 2022, following the FDA clearance of an Investigational New Drug (IND) application for OV329, its GABA-aminotransferase...
September 27, 2022 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics to Present at the Ladenburg Thalmann 2022 Healthcare Conference

NEW YORK, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives...
September 07, 2022 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives...
August 09, 2022 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights

Anticipates filing an Investigational New Drug application for OV329, a potent GABA-aminotransferase inhibitor, and initiating a Phase 1 trial in the second half of 2022 Presented preclinical data...
June 06, 2022 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Presents Preclinical Data on OV329 at the Epilepsy Foundation Pipeline Conference

OV329 demonstrated robust anti-seizure activity in multiple preclinical seizure and epilepsy models, including treatment-resistant seizuresData demonstrate OV329 has the potential for an improved...
May 10, 2022 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Reports First Quarter 2022 Financial Results and Corporate Highlights

Ovid anticipates filing an investigational new drug application (IND) for OV329, a potent GABA aminotransferase inhibitor, and initiating Phase 1 trials in the fourth quarter of 2022Data supporting...
April 08, 2022 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies...